Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

Geron expects 2026 RYTELO revenue of approximately $230 million to $240 million , toward the midpoint to high end of its previously issued $220 million-$240 million guidance. The company reported record quarterly revenue of $57.5 million and three consecutive quarters of growth.

Commercial efforts are shifting toward community oncology practices, which account for about 80% of the lower-risk MDS market. Geron is adding 100 to 200 new RYTELO accounts per quarter, while 34% of business already comes from first- and second-line patients.

Geron plans to outline its European commercialization strategy before year-end and continues the 327-patient IMpactMF Phase 3 trial in relapsed or refractory myelofibrosis. The company ended the period with more than $300 million in cash and reiterated 2026 operating-expense guidance of $230 million-$240 million.

Geron Corporation: FDA Approval Fuels Stock Price Surge

Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $240 million.

Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Semerjian said RYTELO, or imetelstat, was launched in July 2024 as the first telomerase inhibitor for patients with lower-risk myelodysplastic syndromes, or MDS. He described the therapy's mechanism as one designed to target the disease itself rather than mask symptoms.

Geron Stock Doubles After Imetelstat Receives FDA Panel Approval

The company reported $57.5 million in net revenue in its latest quarter, which Semerjian called its highest quarterly sales figure since the launch. Geron has delivered three consecutive quarters of growth, he said, while acknowledging that the company still has work to do to expand use of the drug.

Commercial focus shifts toward community practices

Semerjian said Geron's commercial efforts are increasingly focused on the second-line lower-risk MDS population, particularly within community treatment settings. He said approximately 80% of the business in the disease area is in the community, making simplified physician messaging and engagement with high-volume community accounts important to the launch.